Clinical Trial Update: An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 [Phase 2]

View source ↗

Summary

Adaptive Phase II study of GSK2586184 in Systemic Lupus Erythematosus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• GSK2586184 (GSK2586184)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: TERMINATED